Major Depression Disorder in Adolescents
Status: Open for participation
Research Contact Person: Martha Barron | tel: (520) 626-7325 or email
Principal Investigator: Karen Weihs, MD
The purpose of this study is to evaluate Levomilnacipran ER relative to placebo. The eligibility criteria are for adolescents between 12-17 years of age, inclusive, diagnosed with major depressive disorder. The duration of the study is 9 weeks. For additional infomation and exclusion criteria, please contact Martha Barron at (520) 626-7325.